Seattle Genetics buys Cascadian Therapeutics for $614 million

Cascadian has been doubling down on its lead drug candidate, Tucatinib, currently in a Phase 2 drug trial for treating advanced breast cancer.

Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 31, 2018 Category: Pharmaceuticals Authors: Greg Lamm Source Type: news